News

Filter

Current filters:

HematologyNovo Nordisk

1 to 9 of 10 results

Novo Nordisk gains FDA backing for new NovoSeven RT indication

Novo Nordisk gains FDA backing for new NovoSeven RT indication

09-07-2014

Danish diabetes care giant Novo Nordisk’s hemophilia treatment NovoSeven RT (coagulation factor VIIa…

HematologyNovo NordiskNovoSevenNovoSeven RTPharmaceuticalRare diseasesRegulationUSA

Preventative treatment with NovoEight reduces bleeding in hemophilia A

Preventative treatment with NovoEight reduces bleeding in hemophilia A

12-05-2014

Danish insulin giant Novo Nordisk has announced new Phase III interim data from its guardianT2 trial…

Coagulation systemDenmarkGuardianT2HematologyInsulin giantNovo NordiskNovoEightPharmaceuticalResearchVIII (rFVIII)World Congress

IQWiG finds added benefit for Novo Nordisk’s NovoEight not proven

23-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyHematologyNorthern EuropeNovo NordiskNovoEightPharmaceuticalPricingRegulation

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

31-03-2014

Marking a second regulatory hurdle for the breakthrough product, the US Food and Drug Administration…

AlprolixBenefixBiogen IdecBiotechnologyCSL LimitedHematologyNorth AmericaNovo NordiskPfizerRegulationSwedish Orphan BiovitrumUSA

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

19-03-2014

Danish insulin giant Novo Nordisk says it has completed the pathfinderT2, the first Phase III trial with…

HematologyN8-GPNovo NordiskPharmaceuticalResearchturoctocog alfa

FDA approves Novo Nordisk’s Tretten to treat rare genetic clotting disorder

FDA approves Novo Nordisk’s Tretten to treat rare genetic clotting disorder

24-12-2013

The US Food and Drug Administration yesterday (December 23) approved Tretten, coagulation factor XIII…

HematologyNorth AmericaNovo NordiskNovoThirteenPharmaceuticalRare diseasesRegulationTretten

Novo Nordisk aims to expand its already leading position in diabetes care

Novo Nordisk aims to expand its already leading position in diabetes care

03-12-2013

Denmark-based global insulin giant Novo Nordisk this morning set out its ambition to further expand its…

DiabetesHematologyliraglutideMetabolicsNovo NordiskOG217SCPharmaceuticalsemaglutideVictoza

Novo Nordisk’s NovoEight passes first stage of Japanese approval

Novo Nordisk’s NovoEight passes first stage of Japanese approval

18-11-2013

Danish insulin giant Novo Nordisk’s recombinant factor VIII product NovoEight (turoctocog alfa) has…

Asia-PacificHematologyNovo NordiskNovoEightPharmaceuticalRare diseasesRegulation

1 to 9 of 10 results

Back to top